Daniel Brennan, an analyst from TD Cowen, reiterated the Hold rating on Bruker. The associated price target was lowered to $40.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Daniel Brennan has given his Hold rating due to a combination of factors impacting Bruker’s financial outlook. The company recently revised its 2025 guidance downward following a weak performance, which has raised concerns about its ability to achieve organic growth in 2026. Despite significant cost-cutting measures aimed at protecting earnings per share (EPS) in 2026, demand trends remain weak, and there is limited visibility into future performance.
Bruker’s valuation is near historical lows, which has maintained investor interest, but the risks associated with the EPS guidance and weak demand trends have led to a more cautious outlook. The company’s bookings and orders, particularly from academic and biopharma sectors, have shown significant declines, adding to the uncertainty. While there is potential upside if the US National Institutes of Health (NIH) budget performs better than expected, the current environment suggests maintaining a Hold rating with a reduced price target of $40.
According to TipRanks, Brennan is a 4-star analyst with an average return of 9.0% and a 45.17% success rate. Brennan covers the Healthcare sector, focusing on stocks such as Bruker, Illumina, and Thermo Fisher.
In another report released today, Citi also maintained a Hold rating on the stock with a $38.00 price target.